Industry
Biotechnology
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Loading...
Open
2.52
Mkt cap
5M
Volume
14K
High
2.55
P/E Ratio
-0.20
52-wk high
23.20
Low
2.42
Div yield
N/A
52-wk low
2.41
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:43 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 11:39 am
Portfolio Pulse from Henry Khederian
July 01, 2024 | 6:21 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 4:41 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 11:54 am
Portfolio Pulse from Benzinga Insights
June 11, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.